Cytokine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the cytokine market size is projected to be USD 100.56 billion in 2025, USD 106.14 billion in 2026, and reach USD 149.41 billion by 2031, growing at a CAGR of 7.08% from 2026 to 2031.

This report is Segmented by Product Type (Interleukins, Tumor Necrosis Factor, and More), Therapeutic Application (Cancer & Malignancies, and More), End User (Pharmaceutical & Biotechnology Companies, and More), Function (Pro-Inflammatory Cytokines, and More), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Cytokine Market Trends and Insights

Rising Prevalence of Chronic and Autoimmune Diseases

Escalating autoimmune prevalence is fueling steady cytokine prescribing, especially agents that block interleukin-17, interleukin-23, and TNF pathways. Dupilumab added three new U.S. indications in 2024, lifting revenue expectations above USD 13 billion and highlighting the strategy of extending established antibodies into adjacent diseases. Rheumatoid arthritis, psoriasis, and inflammatory bowel disease affect over 30 million diagnosed U.S. patients, yet injection-site reactions and immunogenicity still curb adherence. Long-acting formulations and subcutaneous devices aim to ease this gap, encouraging payers to authorize at-home use. The cytokine market therefore benefits from both a widening patient pool and therapeutic refinements that improve convenience, creating a virtuous cycle of uptake.

Expanding Oncology Pipeline Using Cytokine-Based Immunotherapies

Cytokines are moving from supportive care to frontline oncology, often paired with checkpoint inhibitors or CAR-T therapies. BNT152 encodes interleukin-2 mRNA inside lipid nanoparticles for intratumoral delivery, limiting systemic exposure while activating local immune cells. Moderna's mRNA-2752 combines interleukin-2 with an OX40 ligand to broaden T-cell activation and entered Phase I trials in 2024. These approaches bypass recombinant protein manufacturing, shortening production cycles from months to weeks. Early data show transient expression of 48-72 hours, so optimal dosing remains uncertain. Nonetheless, positive safety profiles could position these assets to take share from protein-based cytokines in solid tumors by 2030.

High Manufacturing Cost and Complex Purification Requirements

Recombinant cytokines rely on costly mammalian expression systems that demand serum-free media priced at USD 500-1,200 per liter, while multi-step chromatography pushes cost-of-goods for interleukin-2 to USD 8,000-12,000 per gram. Contract manufacturers impose 50 kg minimum orders, requiring upfront commitments exceeding USD 600,000 before clinical proof-of-concept. Smaller sponsors often lack the capital to meet these thresholds, concentrating innovation among cash-rich firms. Emerging markets face added challenges from import tariffs on filtration resins and resupply delays, widening the cost gap and slowing local cytokine market growth. While continuous processing lowers expenses, adoption remains limited to large facilities with robust quality-systems infrastructure.

Other drivers and restraints analyzed in the detailed report include:

1. Advances in Recombinant Engineering & Bioprocessing Technologies
2. mRNA-Encoded, Locally Delivered Cytokine Adjuvants Gaining Traction
3. Dose-Limiting Toxicities Driving Stringent Regulatory Scrutiny

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Interleukins are set to outpace all categories, expanding at a 9.84% CAGR as sponsors pivot from mature TNF franchises to address rare inflammatory disorders. Tumor necrosis factor agents retained 44.36% of 2025 revenue, but biosimilars now pressure prices, pulling AbbVie's Humira down from USD 21.2 billion in 2022 to USD 14.4 billion in 2023. The cytokine market size for interleukins is therefore expected to widen its gap over interferons, whose sales have contracted below USD 500 million as oral antivirals dominate hepatitis care.

Colony-stimulating factors serve a stable supportive-oncology niche, with Zarxio and Nivestym securing 40% of U.S. volume by 2025. Growth factors beyond CSFs, erythropoietin, PDGF, and VEGF, will rise at a 10.13% CAGR (2026-2031), aided by a 35%-cheaper darbepoetin biosimilar approved in 2024. Chemokines remain largely pre-commercial, though CXCR4 antagonists show promise in stem-cell mobilization. Overall, innovators target interleukin-23 and interleukin-6 pathways for their dual autoimmune and oncology potential, injecting fresh momentum into the cytokine market.

Cancer still generated 49.78% of cytokine prescriptions in 2025, reflecting entrenched use of colony-stimulating factors and CAR-T manufacturing cytokines. Yet autoimmune disorders will log the fastest expansion at a 9.54% CAGR, thanks to label extensions for guselkumab, dupilumab, and other interleukin-targeted drugs. The cytokine market size for autoimmune care could surpass oncology by 2031 if current trajectories persist.

Infectious-disease cytokine use is contracting as curative antivirals displace interferon regimens, while inflammatory respiratory disorders converge mechanistically with autoimmune pathways, opening cross-indication leveraging of IL-4, IL-5, and IL-13 blockers. Oral Janus-kinase inhibitors add competitive pressure but often serve as bridge therapy when biologic access is delayed, indirectly supporting ongoing biologic sales.

Complete Report Scope:

• By Product Type
  • Interleukins
  • Tumor Necrosis Factor (TNF)
  • Interferons
  • Colony-Stimulating Factors (CSFs)
  • Chemokines
  • Growth Factors
• By Therapeutic Application
  • Cancer & Malignancies
  • Autoimmune Disorders
  • Infectious Diseases
  • Inflammatory Disorders
  • Others
• By End User
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Hospitals & Diagnostic Laboratories
  • Contract Research Organizations (CROs)
• By Function
  • Pro-inflammatory Cytokines
  • Anti-inflammatory Cytokines
  • Growth & Differentiation Factors
• By Distribution Channel
  • Hospital Pharmacies
  • Specialty Clinics
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 41.53% of 2025 cytokine revenue, sustained by FDA Fast-Track and Priority Review pathways that cut median approval times to nine months. Medicare's 2024 decision to reimburse outpatient CAR-T saved each patient USD 50,000 and widened access beyond academic hospitals. Canada's pan-Canadian Pharmaceutical Alliance forced 25-40% price reductions for biosimilar TNF blockers, accelerating switch rates in Ontario and British Columbia. Mexico approved its first locally made filgrastim biosimilar in 2025, trimming import reliance by 30%.

Asia-Pacific is forecast to post a 10.79% CAGR through 2031, led by China's 18 cytokine biosimilar approvals in 2024 under relaxed rules that allow foreign data and waive local Phase III trials. India earmarked USD 200 million to expand cytokine manufacturing for export, courting Western clients facing supply bottlenecks. Japan aligned its biosimilar review to ICH guidelines, cutting timelines to 16 months and attracting Samsung Biologics and Celltrion investments worth USD 1.2 billion. South Korea's national insurance now covers all approved biosimilars, driving originator-to-biosimilar switching above 60% in hospitals. Australia's 2025 interchangeability rule permits pharmacists to auto-substitute biosimilars, expected to save AUD 300 million (USD 195 million) per year.

Europe accounted for 28% of 2025 sales, concentrated in Germany, France, and the United Kingdom. EMA guidance lets one biosimilarity study unlock approvals across all indications, easing multi-label entry for adalimumab and infliximab copies. Germany enforces 80% prescribing quotas for TNF biosimilars, slashing originator share to 18% by 2025. France now demands clinical superiority for price premiums, squeezing legacy biologics. NICE ties reimbursement to cost-effectiveness thresholds that favor biosimilars below GBP 10,000 per QALY, nudging prescribers away from originators. Brazil, South Africa, and Gulf states round out the landscape as emerging buyers; Brazil's volume-based contracts halved cytokine prices, widening public-system coverage.

1. Abbvie
2. Acro Biosystems
3. Amgen
4. Biogen
5. Bio-Rad Laboratories
6. Bio-Techne / R&D Systems
7. Bristol-Myers Squibb
8. Eli Lilly and Company
9. Roche
10. Gilead Sciences
11. Johnson & Johnson
12. Merck
13. Miltenyi Biotec
14. Novartis
15. Pfizer
16. Regeneron
17. Sanofi
18. Takeda Pharmaceuticals
19. Thermo Fisher Scientific
20. Vertex Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support